XTend Signs Exclusive Global Distribution Agreement With DDI

XTend Medical has received the exclusive global distribution rights to DDI’s vibration device for pre-screening of diabetic neuropathy.

In addition to screening, the device allows patients to monitor their neuropathy levels to help manage their diabetes.

If cleared by the FDA, Xtend will begin marketing the product in the U.S. and hopes to expand into South Korea and the EU. It anticipates the device will have sales of up to $5 million per year in the U.S. and possibly three times that amount globally, according to a company statement.